Hisamitsu Pharmaceutical reports Q2 operating profit decline amid asset drop

Hisamitsu Pharmaceutical Co. Inc. announced consolidated financial results for the second quarter of the fiscal year ending February 2026. Net sales decreased 0.7% to JPY 74,943 million, operating profit fell 9.7% to JPY 8,128 million, and ordinary profit declined 6.5% to JPY 10,089 million. Profit attributable to owners of parent decreased by 22.8% to JPY 7,022 million. Diluted profit per share was JPY 96.88 for the period.

The company's total assets decreased to JPY 336,096 million as of August 31, 2025, from JPY 343,068 million on February 28, 2025. This change includes a reduction in cash and deposits and investment securities, partly offset by an increase in accounts receivable. Shareholder’s equity ratio stood at 79.0%. Hisamitsu confirmed no revisions to its full-year earnings forecast, expecting net sales of JPY 165,000 million and operating profit of JPY 20,000 million.

The company plans an annual dividend of JPY 120.00 per share for the fiscal year ending February 2026, comprising a JPY 90.00 ordinary dividend and a JPY 30.00 commemorative dividend for the 30th anniversary of MOHRUS® Tapes. Hisamitsu also disclosed share repurchases of JPY 7,783 million and the cancellation of 10,000,000 treasury shares on June 12, 2025.